Paradigm Peptides
CLOSEDparadigmpeptides.com
Email me when this record changes
Following this record emails you when it gains a dated entry or its published claims are re-read, and nothing about any other supplier. No topic below is ticked: tick one only if you also want it in the same email.
1 recorded documentation gap also on file, subtracted from the score.
Compiled automatically from the dated observations in this vendor's record. How we evaluate.
Never merged into one number. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Paradigm Peptides is closed: its owner Matthew Kawa was sentenced on July 30, 2026 to 70 months in federal prison with a five million dollar money judgment, after pleading guilty to introducing unapproved drugs into interstate commerce with intent to defraud; his sister Jennifer Stechkober received 16 months in the same case. Federal findings describe forged laboratory certificates and product imported from China and India that was never tested, sold under a claim of being US-made. The original domain, paradigmpeptides.com, returned 403 on every attempt in this record, so nothing on it was read directly; the sites at paradigmpeptides.is and paradigmpeptidesstore.com, each using the Paradigm Peptides name, show conflicting purity claims, one naming HPLC as the method and one not. Does anyone know whether either site is actually connected to the sentenced operators, or just reusing the name?
What the record holds
NONE PUBLISHED
Storefront domain returns HTTP 403 on every path tried, including the shipping and refund policy; secondary sources report the site now shows a closure notice with no orders being fulfilled. No shipping commitment could be read at the source.
No shipping term could be read on this supplier's own pages on 2026-08-20. This publication has never placed an order with any supplier. This row records what is written and measures nothing about what actually happens after an order.
No Trustpilot listing for this supplier could be read on 2026-08-25.
Terminus read the standing of the listing itself and nothing under it. The reviews behind any figure above were not gathered, read, or checked here, and no reader review on this site feeds that number.
This record is older than the re-read program, so no claim-by-claim accounting exists for it yet.
Dated entries
7 observations on file, recorded 2026-08-20. Newest first, appended and never rewritten.
Certificates and testing: NOT VERIFIABLE ON THE SUBJECT DOMAIN. paradigmpeptides.com returned HTTP 403 on every attempt (root and /shop/), and the r.jina.ai text proxy returned HTTP 422 for it, so no product page, certificate page, or policy page on the subject site was read directly. Across all sources reached in this work, ZERO lot numbers, batch codes, test dates, or laboratory names were observed. Nothing quotable exists for those items.
Pricing observed: NO PRICE ON THE SUBJECT DOMAIN COULD BE READ (403). Every price below is from a successor or lookalike domain using the Paradigm Peptides name, exactly as displayed. From paradigmpeptides.is: 1. Semaglutide, 2mg / 5mg / 10mg vials, "Starting from $60.00" (tile also reads 99.4 percent purity with HPLC named as the method, tagged "Bestseller") From paradigmpeptidesstore.com: 2. Tirzepatide, listed as "Tirzepatide GLP-2", $100.00 to $380.00 3.
Shipping and policies: SUBJECT DOMAIN: no policy page could be loaded (403). Secondary sources report the domain now displays a notice that Paradigm Peptides is closed and no orders will be fulfilled. UNVERIFIED by direct observation. Search sources also state existing orders are presumed unrecoverable and that people who believe they are victims can reach a victim-witness specialist at 219-937-5500 in the Northern District of Indiana;
Community record: FINDINGS (court and law enforcement, highest weight): - July 30, 2026: US District Judge Cristal Brisco sentenced Matthew Kawa, owner of Paradigm Peptides, to 70 months in federal prison plus 1 year supervised release, with a $5 million money judgment. His sister Jennifer Stechkober received 16 months. Both pled guilty in December 2025 to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead;
CAUTIONCautions noted: Observations, not verdicts. 1. Unqualified purity claims. paradigmpeptidesstore.com displays a banner claiming 99 percent purity guaranteed with no method named and no batch scope. CBS reports the original site advertised 99 percent purity with no method named. By contrast paradigmpeptides.is does name HPLC alongside its figures, which is the correct form, but pairs it with a catalog-wide average rather than batch-specific data. 2.
Could not be verified: Stated plainly, and this list is long because the brief's core targets could not be met. - THE ENTIRE SUBJECT STOREFRONT. The homepage, product pages, certificate page, and shipping and refund policy of paradigmpeptides.com were NOT read. Root and /shop/ each returned HTTP 403 on repeated attempts. Per instruction I tried the r.jina.ai text proxy once, which returned HTTP 422. No page of the subject domain was ever loaded.
Summary: paradigmpeptides.com should be regarded as defunct rather than as a competitor: its operator Matthew Kawa was sentenced on July 30, 2026 to 70 months in federal prison with a $5 million money judgment after admitting the business forged laboratory certificates, sold product it never tested and imported from China and India while advertising it as US-made, and knew its research-only labeling covered sale for human consumption, with federal testing finding t
Reader reviews
No reader review of this supplier is published yet. Every review is read and checked against the record before it appears. Add a review.
Open this supplier
Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.